Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies
Recently-Acquired BlueRock and AskBio Move Ahead
As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.
